img

Global Neurodegenerative Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Neurodegenerative Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Neurodegenerative drugs are medications used to manage and alleviate symptoms associated with neurodegenerative diseases. They may target various aspects of disease progression, such as cognitive function, motor symptoms, and inflammation.
Global Neurodegenerative Drugs market is projected to reach US$ 173000 million in 2029, increasing from US$ 115030 million in 2022, with the CAGR of 5.9% during the period of 2024 to 2029. Demand from Parkinson’s Disease and Huntington Disease are the major drivers for the industry.
The market for neurodegenerative drugs is driven by the growing burden of neurodegenerative diseases and the need for effective and disease-modifying treatments. The market's growth is also influenced by ongoing research in neuroscience and the development of novel drug candidates targeting specific neurodegenerative pathways.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Neurodegenerative Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Segment by Type
NMDA
SSRIs
Dopamine Inhibitors

Segment by Application


Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Neurodegenerative Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Neurodegenerative Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Neurodegenerative Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Neurodegenerative Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Neurodegenerative Drugs introduction, etc. Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Neurodegenerative Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Neurodegenerative Drugs Market Overview
1.1 Neurodegenerative Drugs Product Overview
1.2 Neurodegenerative Drugs Market Segment by Type
1.2.1 NMDA
1.2.2 SSRIs
1.2.3 Dopamine Inhibitors
1.3 Global Neurodegenerative Drugs Market Size by Type
1.3.1 Global Neurodegenerative Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Neurodegenerative Drugs Historic Market Size Review by Type (2018-2024)
1.3.3 Global Neurodegenerative Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Neurodegenerative Drugs Sales Breakdown by Type (2018-2024)
1.4.2 Europe Neurodegenerative Drugs Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Neurodegenerative Drugs Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Neurodegenerative Drugs Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Neurodegenerative Drugs Sales Breakdown by Type (2018-2024)
2 Global Neurodegenerative Drugs Market Competition by Company
2.1 Global Top Players by Neurodegenerative Drugs Sales (2018-2024)
2.2 Global Top Players by Neurodegenerative Drugs Revenue (2018-2024)
2.3 Global Top Players by Neurodegenerative Drugs Price (2018-2024)
2.4 Global Top Manufacturers Neurodegenerative Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Neurodegenerative Drugs Market Competitive Situation and Trends
2.5.1 Neurodegenerative Drugs Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Neurodegenerative Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neurodegenerative Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Neurodegenerative Drugs Market
2.8 Key Manufacturers Neurodegenerative Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Neurodegenerative Drugs Status and Outlook by Region
3.1 Global Neurodegenerative Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Neurodegenerative Drugs Historic Market Size by Region
3.2.1 Global Neurodegenerative Drugs Sales in Volume by Region (2018-2024)
3.2.2 Global Neurodegenerative Drugs Sales in Value by Region (2018-2024)
3.2.3 Global Neurodegenerative Drugs Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Neurodegenerative Drugs Forecasted Market Size by Region
3.3.1 Global Neurodegenerative Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Neurodegenerative Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Neurodegenerative Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Neurodegenerative Drugs by Application
4.1 Neurodegenerative Drugs Market Segment by Application
4.1.1 Parkinson’s Disease
4.1.2 Huntington Disease
4.1.3 Amyotrophic Lateral Sclerosis
4.1.4 Alzheimer’s Disease
4.2 Global Neurodegenerative Drugs Market Size by Application
4.2.1 Global Neurodegenerative Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Neurodegenerative Drugs Historic Market Size Review by Application (2018-2024)
4.2.3 Global Neurodegenerative Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Neurodegenerative Drugs Sales Breakdown by Application (2018-2024)
4.3.2 Europe Neurodegenerative Drugs Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Neurodegenerative Drugs Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Neurodegenerative Drugs Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Neurodegenerative Drugs Sales Breakdown by Application (2018-2024)
5 North America Neurodegenerative Drugs by Country
5.1 North America Neurodegenerative Drugs Historic Market Size by Country
5.1.1 North America Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Neurodegenerative Drugs Sales in Volume by Country (2018-2024)
5.1.3 North America Neurodegenerative Drugs Sales in Value by Country (2018-2024)
5.2 North America Neurodegenerative Drugs Forecasted Market Size by Country
5.2.1 North America Neurodegenerative Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Neurodegenerative Drugs Sales in Value by Country (2024-2029)
6 Europe Neurodegenerative Drugs by Country
6.1 Europe Neurodegenerative Drugs Historic Market Size by Country
6.1.1 Europe Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Neurodegenerative Drugs Sales in Volume by Country (2018-2024)
6.1.3 Europe Neurodegenerative Drugs Sales in Value by Country (2018-2024)
6.2 Europe Neurodegenerative Drugs Forecasted Market Size by Country
6.2.1 Europe Neurodegenerative Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Neurodegenerative Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Neurodegenerative Drugs by Region
7.1 Asia-Pacific Neurodegenerative Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Neurodegenerative Drugs Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Neurodegenerative Drugs Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Neurodegenerative Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Neurodegenerative Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Neurodegenerative Drugs Sales in Value by Region (2024-2029)
8 Latin America Neurodegenerative Drugs by Country
8.1 Latin America Neurodegenerative Drugs Historic Market Size by Country
8.1.1 Latin America Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Neurodegenerative Drugs Sales in Volume by Country (2018-2024)
8.1.3 Latin America Neurodegenerative Drugs Sales in Value by Country (2018-2024)
8.2 Latin America Neurodegenerative Drugs Forecasted Market Size by Country
8.2.1 Latin America Neurodegenerative Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Neurodegenerative Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Neurodegenerative Drugs by Country
9.1 Middle East and Africa Neurodegenerative Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Neurodegenerative Drugs Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Neurodegenerative Drugs Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Neurodegenerative Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Neurodegenerative Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Neurodegenerative Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Novartis
10.1.1 Novartis Company Information
10.1.2 Novartis Introduction and Business Overview
10.1.3 Novartis Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Novartis Neurodegenerative Drugs Products Offered
10.1.5 Novartis Recent Development
10.2 Pfizer
10.2.1 Pfizer Company Information
10.2.2 Pfizer Introduction and Business Overview
10.2.3 Pfizer Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Pfizer Neurodegenerative Drugs Products Offered
10.2.5 Pfizer Recent Development
10.3 Merck Serono
10.3.1 Merck Serono Company Information
10.3.2 Merck Serono Introduction and Business Overview
10.3.3 Merck Serono Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Merck Serono Neurodegenerative Drugs Products Offered
10.3.5 Merck Serono Recent Development
10.4 Biogen Idec
10.4.1 Biogen Idec Company Information
10.4.2 Biogen Idec Introduction and Business Overview
10.4.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Biogen Idec Neurodegenerative Drugs Products Offered
10.4.5 Biogen Idec Recent Development
10.5 TEVA
10.5.1 TEVA Company Information
10.5.2 TEVA Introduction and Business Overview
10.5.3 TEVA Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.5.4 TEVA Neurodegenerative Drugs Products Offered
10.5.5 TEVA Recent Development
10.6 UCB
10.6.1 UCB Company Information
10.6.2 UCB Introduction and Business Overview
10.6.3 UCB Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.6.4 UCB Neurodegenerative Drugs Products Offered
10.6.5 UCB Recent Development
10.7 Boehringer Ingelheim
10.7.1 Boehringer Ingelheim Company Information
10.7.2 Boehringer Ingelheim Introduction and Business Overview
10.7.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Boehringer Ingelheim Neurodegenerative Drugs Products Offered
10.7.5 Boehringer Ingelheim Recent Development
10.8 Sanofi
10.8.1 Sanofi Company Information
10.8.2 Sanofi Introduction and Business Overview
10.8.3 Sanofi Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Sanofi Neurodegenerative Drugs Products Offered
10.8.5 Sanofi Recent Development
10.9 GlaxoSmithKline
10.9.1 GlaxoSmithKline Company Information
10.9.2 GlaxoSmithKline Introduction and Business Overview
10.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.9.4 GlaxoSmithKline Neurodegenerative Drugs Products Offered
10.9.5 GlaxoSmithKline Recent Development
10.10 Livzon Pharmaceutical
10.10.1 Livzon Pharmaceutical Company Information
10.10.2 Livzon Pharmaceutical Introduction and Business Overview
10.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Products Offered
10.10.5 Livzon Pharmaceutical Recent Development
10.11 Haisco Pharmaceutical
10.11.1 Haisco Pharmaceutical Company Information
10.11.2 Haisco Pharmaceutical Introduction and Business Overview
10.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Products Offered
10.11.5 Haisco Pharmaceutical Recent Development
10.12 Jingxin Pharmaceutical
10.12.1 Jingxin Pharmaceutical Company Information
10.12.2 Jingxin Pharmaceutical Introduction and Business Overview
10.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Jingxin Pharmaceutical Neurodegenerative Drugs Products Offered
10.12.5 Jingxin Pharmaceutical Recent Development
10.13 Dongcheng Biochemicals
10.13.1 Dongcheng Biochemicals Company Information
10.13.2 Dongcheng Biochemicals Introduction and Business Overview
10.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Dongcheng Biochemicals Neurodegenerative Drugs Products Offered
10.13.5 Dongcheng Biochemicals Recent Development
10.14 Hisun Pharmaceutical
10.14.1 Hisun Pharmaceutical Company Information
10.14.2 Hisun Pharmaceutical Introduction and Business Overview
10.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.14.4 Hisun Pharmaceutical Neurodegenerative Drugs Products Offered
10.14.5 Hisun Pharmaceutical Recent Development
10.15 Luye Pharma
10.15.1 Luye Pharma Company Information
10.15.2 Luye Pharma Introduction and Business Overview
10.15.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.15.4 Luye Pharma Neurodegenerative Drugs Products Offered
10.15.5 Luye Pharma Recent Development
10.16 Ark Pharmaceutical
10.16.1 Ark Pharmaceutical Company Information
10.16.2 Ark Pharmaceutical Introduction and Business Overview
10.16.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.16.4 Ark Pharmaceutical Neurodegenerative Drugs Products Offered
10.16.5 Ark Pharmaceutical Recent Development
10.17 Kanghong Pharmaceutical
10.17.1 Kanghong Pharmaceutical Company Information
10.17.2 Kanghong Pharmaceutical Introduction and Business Overview
10.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.17.4 Kanghong Pharmaceutical Neurodegenerative Drugs Products Offered
10.17.5 Kanghong Pharmaceutical Recent Development
10.18 Huahai Pharmaceutical
10.18.1 Huahai Pharmaceutical Company Information
10.18.2 Huahai Pharmaceutical Introduction and Business Overview
10.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.18.4 Huahai Pharmaceutical Neurodegenerative Drugs Products Offered
10.18.5 Huahai Pharmaceutical Recent Development
10.19 BORA PHARMACEUTICALS
10.19.1 BORA PHARMACEUTICALS Company Information
10.19.2 BORA PHARMACEUTICALS Introduction and Business Overview
10.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2024)
10.19.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Products Offered
10.19.5 BORA PHARMACEUTICALS Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Neurodegenerative Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Neurodegenerative Drugs Industrial Chain Analysis
11.4 Neurodegenerative Drugs Market Dynamics
11.4.1 Neurodegenerative Drugs Industry Trends
11.4.2 Neurodegenerative Drugs Market Drivers
11.4.3 Neurodegenerative Drugs Market Challenges
11.4.4 Neurodegenerative Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Neurodegenerative Drugs Distributors
12.3 Neurodegenerative Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of NMDA
Table 2. Major Company of SSRIs
Table 3. Major Company of Dopamine Inhibitors
Table 4. Global Neurodegenerative Drugs Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Neurodegenerative Drugs Sales by Type (2018-2024) & (MT)
Table 6. Global Neurodegenerative Drugs Sales Market Share in Volume by Type (2018-2024)
Table 7. Global Neurodegenerative Drugs Sales by Type (2018-2024) & (US& Million)
Table 8. Global Neurodegenerative Drugs Market Share in Value by Type (2018-2024)
Table 9. Global Neurodegenerative Drugs Price by Type (2018-2024) & (US$/MT)
Table 10. Global Neurodegenerative Drugs Sales by Type (2024-2029) & (MT)
Table 11. Global Neurodegenerative Drugs Sales Market Share in Volume by Type (2024-2029)
Table 12. Global Neurodegenerative Drugs Sales by Type (2024-2029) & (US$ Million)
Table 13. Global Neurodegenerative Drugs Sales Market Share in Value by Type (2024-2029)
Table 14. Global Neurodegenerative Drugs Price by Type (2024-2029) & (US$/MT)
Table 15. North America Neurodegenerative Drugs Sales by Type (2018-2024) & (MT)
Table 16. North America Neurodegenerative Drugs Sales by Type (2018-2024) & (US$ Million)
Table 17. Europe Neurodegenerative Drugs Sales (MT) by Type (2018-2024)
Table 18. Europe Neurodegenerative Drugs Sales by Type (2018-2024) & (US$ Million)
Table 19. Asia-Pacific Neurodegenerative Drugs Sales (MT) by Type (2018-2024)
Table 20. Asia-Pacific Neurodegenerative Drugs Sales by Type (2018-2024) & (US$ Million)
Table 21. Latin America Neurodegenerative Drugs Sales (MT) by Type (2018-2024)
Table 22. Latin America Neurodegenerative Drugs Sales by Type (2018-2024) & (US$ Million)
Table 23. Middle East and Africa Neurodegenerative Drugs Sales (MT) by Type (2018-2024)
Table 24. Middle East and Africa Neurodegenerative Drugs Sales by Type (2018-2024) & (US$ Million)
Table 25. Global Neurodegenerative Drugs Sales by Company (2018-2024) & (MT)
Table 26. Global Neurodegenerative Drugs Sales Share by Company (2018-2024)
Table 27. Global Neurodegenerative Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 28. Global Neurodegenerative Drugs Revenue Share by Company (2018-2024)
Table 29. Global Market Neurodegenerative Drugs Price by Company (2018-2024) & (US$/MT)
Table 30. Global Neurodegenerative Drugs Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 31. Global Neurodegenerative Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 32. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neurodegenerative Drugs as of 2022)
Table 33. Date of Key Manufacturers Enter into Neurodegenerative Drugs Market
Table 34. Key Manufacturers Neurodegenerative Drugs Product Type
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Neurodegenerative Drugs Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 37. Global Neurodegenerative Drugs Sales by Region (2018-2024) & (MT)
Table 38. Global Neurodegenerative Drugs Sales Market Share in Volume by Region (2018-2024)
Table 39. Global Neurodegenerative Drugs Sales by Region (2018-2024) & (US$ Million)
Table 40. Global Neurodegenerative Drugs Sales Market Share in Value by Region (2018-2024)
Table 41. Global Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2024)
Table 42. Global Neurodegenerative Drugs Sales by Region (2024-2029) & (MT)
Table 43. Global Neurodegenerative Drugs Sales Market Share in Volume by Region (2024-2029)
Table 44. Global Neurodegenerative Drugs Sales by Region (2024-2029) & (US$ Million)
Table 45. Global Neurodegenerative Drugs Sales Market Share in Value by Region (2024-2029)
Table 46. Global Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2024-2029)
Table 47. Global Neurodegenerative Drugs Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 48. Global Neurodegenerative Drugs Sales by Application (2018-2024) & (MT)
Table 49. Global Neurodegenerative Drugs Sales Market Share in Volume by Application (2018-2024)
Table 50. Global Neurodegenerative Drugs Sales by Application (2018-2024) & (US$ Million)
Table 51. Global Neurodegenerative Drugs Sales Market Share in Value by Application (2018-2024)
Table 52. Global Neurodegenerative Drugs Price by Application (2018-2024) & (US$/MT)
Table 53. Global Neurodegenerative Drugs Sales by Application (2024-2029) & (MT)
Table 54. Global Neurodegenerative Drugs Sales Market Share in Volume by Application (2024-2029)
Table 55. Global Neurodegenerative Drugs Sales by Application (2024-2029) & (US$ Million)
Table 56. Global Neurodegenerative Drugs Sales Market Share in Value by Application (2024-2029)
Table 57. Global Neurodegenerative Drugs Price by Application (2024-2029) & (US$/MT)
Table 58. North America Neurodegenerative Drugs Sales by Application (2018-2024) (MT)
Table 59. North America Neurodegenerative Drugs Sales by Application (2018-2024) & (US$ Million)
Table 60. Europe Neurodegenerative Drugs Sales by Application (2018-2024) (MT)
Table 61. Europe Neurodegenerative Drugs Sales by Application (2018-2024) & (US$ Million)
Table 62. Asia-Pacific Neurodegenerative Drugs Sales by Application (2018-2024) (MT)
Table 63. Asia-Pacific Neurodegenerative Drugs Sales by Application (2018-2024) & (US$ Million)
Table 64. Latin America Neurodegenerative Drugs Sales by Application (2018-2024) (MT)
Table 65. Latin America Neurodegenerative Drugs Sales by Application (2018-2024) & (US$ Million)
Table 66. Middle East and Africa Neurodegenerative Drugs Sales by Application (2018-2024) (MT)
Table 67. Middle East and Africa Neurodegenerative Drugs Sales by Application (2018-2024) & (US$ Million)
Table 68. North America Neurodegenerative Drugs Sales by Country (2018-2024) & (MT)
Table 69. North America Neurodegenerative Drugs Sales Market Share in Volume by Country (2018-2024)
Table 70. North America Neurodegenerative Drugs Sales by Country (2018-2024) & (US$ Million)
Table 71. North America Neurodegenerative Drugs Sales Market Share in Value by Country (2018-2024)
Table 72. North America Neurodegenerative Drugs Sales by Country (2024-2029) & (MT)
Table 73. North America Neurodegenerative Drugs Sales Market Share in Volume by Country (2024-2029)
Table 74. North America Neurodegenerative Drugs Sales by Country (2024-2029) & (US$ Million)
Table 75. North America Neurodegenerative Drugs Sales Market Share in Value by Country (2024-2029)
Table 76. Europe Neurodegenerative Drugs Sales by Country (2018-2024) & (MT)
Table 77. Europe Neurodegenerative Drugs Sales Market Share in Volume by Country (2018-2024)
Table 78. Europe Neurodegenerative Drugs Sales by Country (2018-2024) & (US$ Million)
Table 79. Europe Neurodegenerative Drugs Sales Market Share in Value by Country (2018-2024)
Table 80. Europe Neurodegenerative Drugs Sales by Country (2024-2029) & (MT)
Table 81. Europe Neurodegenerative Drugs Sales Market Share in Volume by Country (2024-2029)
Table 82. Europe Neurodegenerative Drugs Sales by Country (2024-2029) & (US$ Million)
Table 83. Europe Neurodegenerative Drugs Sales Market Share in Value by Country (2024-2029)
Table 84. Asia-Pacific Neurodegenerative Drugs Sales by Region (2018-2024) & (MT)
Table 85. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Volume by Region (2018-2024)
Table 86. Asia-Pacific Neurodegenerative Drugs Sales by Region (2018-2024) & (US$ Million)
Table 87. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Value by Region (2018-2024)
Table 88. Asia-Pacific Neurodegenerative Drugs Sales by Region (2024-2029) & (MT)
Table 89. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Volume by Region (2024-2029)
Table 90. Asia-Pacific Neurodegenerative Drugs Sales by Region (2024-2029) & (US$ Million)
Table 91. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Value by Region (2024-2029)
Table 92. Latin America Neurodegenerative Drugs Sales by Country (2018-2024) & (MT)
Table 93. Latin America Neurodegenerative Drugs Sales Market Share in Volume by Country (2018-2024)
Table 94. Latin America Neurodegenerative Drugs Sales by Country (2018-2024) & (US$ Million)
Table 95. Latin America Neurodegenerative Drugs Sales Market Share in Value by Country (2018-2024)
Table 96. Latin America Neurodegenerative Drugs Sales by Country (2024-2029) & (MT)
Table 97. Latin America Neurodegenerative Drugs Sales Market Share in Volume by Country (2024-2029)
Table 98. Latin America Neurodegenerative Drugs Sales by Country (2024-2029) & (US$ Million)
Table 99. Latin America Neurodegenerative Drugs Sales Market Share in Value by Country (2024-2029)
Table 100. Middle East and Africa Neurodegenerative Drugs Sales by Country (2018-2024) & (MT)
Table 101. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Volume by Country (2018-2024)
Table 102. Middle East and Africa Neurodegenerative Drugs Sales by Country (2018-2024) & (US$ Million)
Table 103. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Value by Country (2018-2024)
Table 104. Middle East and Africa Neurodegenerative Drugs Sales by Country (2024-2029) & (MT)
Table 105. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Volume by Country (2024-2029)
Table 106. Middle East and Africa Neurodegenerative Drugs Sales by Country (2024-2029) & (US$ Million)
Table 107. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Value by Country (2024-2029)
Table 108. Novartis Company Information
Table 109. Novartis Introduction and Business Overview
Table 110. Novartis Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 111. Novartis Neurodegenerative Drugs Product
Table 112. Novartis Recent Development
Table 113. Pfizer Company Information
Table 114. Pfizer Introduction and Business Overview
Table 115. Pfizer Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 116. Pfizer Neurodegenerative Drugs Product
Table 117. Pfizer Recent Development
Table 118. Merck Serono Company Information
Table 119. Merck Serono Introduction and Business Overview
Table 120. Merck Serono Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 121. Merck Serono Neurodegenerative Drugs Product
Table 122. Merck Serono Recent Development
Table 123. Biogen Idec Company Information
Table 124. Biogen Idec Introduction and Business Overview
Table 125. Biogen Idec Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 126. Biogen Idec Neurodegenerative Drugs Product
Table 127. Biogen Idec Recent Development
Table 128. TEVA Company Information
Table 129. TEVA Introduction and Business Overview
Table 130. TEVA Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 131. TEVA Neurodegenerative Drugs Product
Table 132. TEVA Recent Development
Table 133. UCB Company Information
Table 134. UCB Introduction and Business Overview
Table 135. UCB Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 136. UCB Neurodegenerative Drugs Product
Table 137. UCB Recent Development
Table 138. Boehringer Ingelheim Company Information
Table 139. Boehringer Ingelheim Introduction and Business Overview
Table 140. Boehringer Ingelheim Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 141. Boehringer Ingelheim Neurodegenerative Drugs Product
Table 142. Boehringer Ingelheim Recent Development
Table 143. Sanofi Company Information
Table 144. Sanofi Introduction and Business Overview
Table 145. Sanofi Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 146. Sanofi Neurodegenerative Drugs Product
Table 147. Sanofi Recent Development
Table 148. GlaxoSmithKline Company Information
Table 149. GlaxoSmithKline Introduction and Business Overview
Table 150. GlaxoSmithKline Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 151. GlaxoSmithKline Neurodegenerative Drugs Product
Table 152. GlaxoSmithKline Recent Development
Table 153. Livzon Pharmaceutical Company Information
Table 154. Livzon Pharmaceutical Introduction and Business Overview
Table 155. Livzon Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 156. Livzon Pharmaceutical Neurodegenerative Drugs Product
Table 157. Livzon Pharmaceutical Recent Development
Table 158. Haisco Pharmaceutical Company Information
Table 159. Haisco Pharmaceutical Introduction and Business Overview
Table 160. Haisco Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 161. Haisco Pharmaceutical Neurodegenerative Drugs Product
Table 162. Haisco Pharmaceutical Recent Development
Table 163. Jingxin Pharmaceutical Company Information
Table 164. Jingxin Pharmaceutical Introduction and Business Overview
Table 165. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 166. Jingxin Pharmaceutical Neurodegenerative Drugs Product
Table 167. Jingxin Pharmaceutical Recent Development
Table 168. Dongcheng Biochemicals Company Information
Table 169. Dongcheng Biochemicals Introduction and Business Overview
Table 170. Dongcheng Biochemicals Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 171. Dongcheng Biochemicals Neurodegenerative Drugs Product
Table 172. Dongcheng Biochemicals Recent Development
Table 173. Hisun Pharmaceutical Company Information
Table 174. Hisun Pharmaceutical Introduction and Business Overview
Table 175. Hisun Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 176. Hisun Pharmaceutical Neurodegenerative Drugs Product
Table 177. Hisun Pharmaceutical Recent Development
Table 178. Luye Pharma Company Information
Table 179. Luye Pharma Introduction and Business Overview
Table 180. Luye Pharma Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 181. Luye Pharma Neurodegenerative Drugs Product
Table 182. Luye Pharma Recent Development
Table 183. Ark Pharmaceutical Company Information
Table 184. Ark Pharmaceutical Introduction and Business Overview
Table 185. Ark Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 186. Ark Pharmaceutical Neurodegenerative Drugs Product
Table 187. Ark Pharmaceutical Recent Development
Table 188. Kanghong Pharmaceutical Company Information
Table 189. Kanghong Pharmaceutical Introduction and Business Overview
Table 190. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 191. Kanghong Pharmaceutical Neurodegenerative Drugs Product
Table 192. Kanghong Pharmaceutical Recent Development
Table 193. Huahai Pharmaceutical Company Information
Table 194. Huahai Pharmaceutical Introduction and Business Overview
Table 195. Huahai Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 196. Huahai Pharmaceutical Neurodegenerative Drugs Product
Table 197. Huahai Pharmaceutical Recent Development
Table 198. BORA PHARMACEUTICALS Company Information
Table 199. BORA PHARMACEUTICALS Introduction and Business Overview
Table 200. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2024)
Table 201. BORA PHARMACEUTICALS Neurodegenerative Drugs Product
Table 202. BORA PHARMACEUTICALS Recent Development
Table 203. Key Raw Materials Lists
Table 204. Raw Materials Key Suppliers Lists
Table 205. Neurodegenerative Drugs Market Trends
Table 206. Neurodegenerative Drugs Market Drivers
Table 207. Neurodegenerative Drugs Market Challenges
Table 208. Neurodegenerative Drugs Market Restraints
Table 209. Neurodegenerative Drugs Distributors List
Table 210. Neurodegenerative Drugs Downstream Customers
Table 211. Research Programs/Design for This Report
Table 212. Key Data Information from Secondary Sources
Table 213. Key Data Information from Primary Sources
List of Figures
Figure 1. Neurodegenerative Drugs Product Picture
Figure 2. Global Neurodegenerative Drugs Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Neurodegenerative Drugs Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Neurodegenerative Drugs Sales Status and Outlook (2018-2029) & (MT)
Figure 5. Product Picture of NMDA
Figure 6. Global NMDA Sales YoY Growth (2018-2029) & (MT)
Figure 7. Product Picture of SSRIs
Figure 8. Global SSRIs Sales YoY Growth (2018-2029) & (MT)
Figure 9. Product Picture of Dopamine Inhibitors
Figure 10. Global Dopamine Inhibitors Sales YoY Growth (2018-2029) & (MT)
Figure 11. Global Neurodegenerative Drugs Sales by Type (2018-2029) & (US$ Million)
Figure 12. Global Neurodegenerative Drugs Sales Market Share by Type in 2022 & 2029
Figure 13. North America Neurodegenerative Drugs Sales Market Share in Volume by Type in 2022
Figure 14. North America Neurodegenerative Drugs Sales Market Share in Value by Type in 2022
Figure 15. Europe Neurodegenerative Drugs Sales Market Share in Volume by Type in 2022
Figure 16. Europe Neurodegenerative Drugs Sales Market Share in Value by Type in 2022
Figure 17. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Volume by Type in 2022
Figure 18. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Value by Type in 2022
Figure 19. Latin America Neurodegenerative Drugs Sales Market Share in Volume by Type in 2022
Figure 20. Latin America Neurodegenerative Drugs Sales Market Share in Value by Type in 2022
Figure 21. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Volume by Type in 2022
Figure 22. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Value by Type in 2022
Figure 23. The 5 and 10 Largest Manufacturers in the World: Market Share by Neurodegenerative Drugs Sales in 2022
Figure 24. The 5 and 10 Largest Manufacturers in the World: Market Share by Neurodegenerative Drugs Revenue in 2022
Figure 25. Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 26. Product Picture of Parkinson’s Disease
Figure 27. Global Parkinson’s Disease Sales YoY Growth (2018-2029) & (MT)
Figure 28. Product Picture of Huntington Disease
Figure 29. Global Huntington Disease Sales YoY Growth (2018-2029) & (MT)
Figure 30. Product Picture of Amyotrophic Lateral Sclerosis
Figure 31. Global Amyotrophic Lateral Sclerosis Sales YoY Growth (2018-2029) & (MT)
Figure 32. Product Picture of Alzheimer’s Disease
Figure 33. Global Alzheimer’s Disease Sales YoY Growth (2018-2029) & (MT)
Figure 34. Global Neurodegenerative Drugs Sales by Application (2018-2029) & (US$ Million)
Figure 35. Global Neurodegenerative Drugs Sales Market Share by Application in 2022 & 2029
Figure 36. North America Neurodegenerative Drugs Sales Market Share in Volume by Application in 2022
Figure 37. North America Neurodegenerative Drugs Sales Market Share in Value by Application in 2022
Figure 38. Europe Neurodegenerative Drugs Sales Market Share in Volume by Application in 2022
Figure 39. Europe Neurodegenerative Drugs Sales Market Share in Value by Application in 2022
Figure 40. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Volume by Application in 2022
Figure 41. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Value by Application in 2022
Figure 42. Latin America Neurodegenerative Drugs Sales Market Share in Volume by Application in 2022
Figure 43. Latin America Neurodegenerative Drugs Sales Market Share in Value by Application in 2022
Figure 44. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Value by Application in 2022
Figure 45. Key Raw Materials Price
Figure 46. Neurodegenerative Drugs Manufacturing Cost Structure
Figure 47. Neurodegenerative Drugs Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries